Teva, Cancer Research U.K. in cancer deal

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Cancer Research Technology Ltd. (CRT), the commercial arm of Cancer Research U.K., partnered to discover drugs that modulate DNA damage and repair response processes in cancer cells. CRT will select and validate undisclosed novel targets. The partners will jointly undertake chemical lead generation activities. CRT will receive undisclosed research funding and will be eligible for milestones and royalties. The partners could not be reached for details. Teva was off $0.46 to $37.88 on Monday. ...